Pheon Therapeutics
13 posts

Pheon Therapeutics
@pheontx
Pheon Therapeutics is a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers.
London, AL5 2JQ, UK Katılım Temmuz 2022
0 Takip Edilen64 Takipçiler

@pheontx is pleased to announce 📢 the appointment of accomplished biotech executive, Enoch Kariuki, PharmD, to its Board of Directors as an independent, non-executive director! Read more about Dr. Kariuki's experience in the PR 🗞️, linked in the comments below👇.
GIF
English

@Pheontx is excited to announce 📣 the completion of a $120 million #SeriesBfinancing to advance its differentiated #ADC pipeline through proof of concept. Led by TCGX, we welcome Cariad Chester to the board. Stay tuned for more updates coming soon! Link to PR in the thread!
GIF
English

@Pheon_tx is set to be in San Francisco next week, 8-11 January, for the 42nd Annual @jpmorgan Healthcare Conference. Get in touch if you would like to meet with our CEO, Cyrus Mozayeni. #JPM2024 #PheonTherapeutics #Oncology #Innovation #ADCs

English

@pheontx is pleased to announce the appointment of #oncology expert Arvin Yang, MD, PhD as its new CMO. As a seasoned CMO with over a decade of experience in advancing oncology therapies, he joins us to advance #ADCs for treatment of solid tumors. bit.ly/45qaxJE

English

Welcome to Jeff Albers on his appointment as Chairman of the @Pheon_tx Board of Directors.
#ADCs #oncology #CompanyGrowth #clinicaldevelopment

English

@Pheon_tx proudly welcomes Cyrus Mozayeni as its new CEO. With 20+ years of biotech expertise, Cyrus will lead the Company in the next stage of Company growth as we advance our #ADC program targeting hard-to-treat cancers into the clinic. Read more: bit.ly/3O8PDYF

English

@Pheon_tx will develop and commercialize an antibody using @Biocytogen's proprietary #RenMice platform to develop a best-in-class ADC as part of an exclusive licensing agreement.
Read more here: bit.ly/44x1ab6
English

We are delighted to announce the successful launch of @pheontx with a $68M #SeriesA to advance novel Antibody-Drug Conjugates for a wide range of hard-to-treat #cancers.
Read more: bit.ly/3y0vzRf
#pheontx #ADCs #solidtumors #biotech

English

